Pierce/Amyloid beta 42 Human ELISA Kit, Ultrasensitive/96 tests/KHB3544

Description

TheHumanBetaAmyloid[1-42]Ultrasensitive(Aβ42US)ELISAresearch-use-onlykitistobeusedforthequantitativedeterminationofHumanAβ42insamples(e.g.,cellculturesupernatants,tissuehomogenates,cerebrospinalfluid[CSF],etc.)using96-wellplatesandamicroplatereader.TheassayrecognizesbothnaturalandsyntheticformsofhumanAβ42.Theanti-humanAβ42antibodyusedinthiskitiscapableofselectivelydetectingAβ42andnotAβ40/Aβ43.*

Performancecharacteristics
•Sensitivity:<1>
•Standardcurverange:1.56–100pg/mL
•Sampletypes:cellculturesupernatants,tissuehomogenates,cerebrospinalfluid(CSF)
•Speciescross-reactivity:human
•Samplevolume:50μL(prediluted)
•Totalassayincubationtime:4hrs

Principleofthemethod
TheHumanAβ42USkitisasolidphasesandwichenzyme-linkedimmunosorbentassay(ELISA).AmonoclonalantibodyspecificfortheNH₂-terminusofhumanAβhasbeencoatedontothewellsofthemicrotiterstripsprovided.Samples,includingstandardsofknownhumanAβcontent,controlspecimensandunknownsarePipettedintothesewells,andco-incubatedwitharabbitmonoclonalantibody*specificfortheCOOH-terminusofthe1-42Aβsequence.ThisCOOH-terminalsequenceiscreateduponcleavageoftheanalyzedprecursor.

BoundrabbitantibodyisdetectedbytheuseofahorserADIshperoxidase-labeledanti-rabbitantibody.Afterremovalofexcessanti-rabbitantibody,asubstratesolutionisadded,whichisacteduponbytheboundenzymetoproducecolor.TheintensityofthiscoloredproductisdirectlyproportionaltotheconcentrationofhumanAβ42presentintheoriginalspecimen.

Backgroundinformation
Alzheimer’sDisease(AD)ischaracterizedbythepresenceofextracellularplaquesandintracellularneurofibrillarytangles(NFTs)inthebrain.Themajorproteincomponentoftheseplaquesisβamyloidpeptide(Aβ),a40to43aminoacidpeptidecleavedfromamyloidprecursorproteinbyβ-secretase(i.e.,BACE)andaputativeγ(gamma)secretase.IncreasedreleaseofthelongerformsofAβpeptide,Aβ42orAβ43,whichhaveagreatertendencytoaggregatethanAβ40,occursinindividualsexpressingcertaingeneticmutations,expressingcertainApoEalleles,ormayinvolveother,stillundiscovered,factors.ManyresearcherstheorizethatitisthisincreasedreleaseofAβ42/Aβ43thatleadstotheabnormaldepositionofAβandtheassociatedneurotoxicityinthebrainsofaffectedindividuals.

EachHumanAβ42USELISAkitisvalidatedforsensitivity,specificity,precision,andlot-to-lotconsistency.Seeproductinsertformoreinformationonvalidation.

Relatedlinks
LearnmoreaboutELISAkits
Learnmoreaboutotherimmunoassays

*PleaserefertotheELISAprotocolforspecificreferencecitations.